Event Details
- Location: Berlin, Germany
- Dates: Wednesday 16th September to Friday 18th September 2015
- Price: €
(Non-Members: €1025.00)
‘The Disappearing Deal World?’
How Companies Secure Deals in an Environment of
Big Pharma M&A and Strategic Alliances
We are pleased to announce the XII International Pharma Licensing Symposium, hosted by the Pharma Lizenz Club Deutschland (PLCD), will be held on 16th – 18th September 2015 at the Hilton Berlin, Germany.
Details of the 3 day programme will be announced very shortly but the highlights of the event will include:
– Access to Online Delegate Contact Systen
– Private Area for One-to-One Meetings
– Presentations from Speakers within the Indsutry
– ‘Interactive ‘Talking Tables’ and Panel Discussions
– Informal Networking Opportunites
– Welcome Drinks Reception plus Gala Dinner at The Adagio
‘Since I started to attend your conference three years ago, about USD150m investment in 5 deals has been done. Of these 5 deals, at least two of them (more than USD 100m) are coming from the leads, generated from the one2one meetings in your conference. I feel that I own a great debt to your conference’
Previous IPLS delegate
Programme (please see full programme below) – to include:
– Overview of what is happening in the deal environment
– Panel sessions featuring different healthcare sectors explaing how M&A affects their business
– Consolidation and risk sharing between big pharma companies
– 6 ‘Talking Table’ topics – Good Partnering Practices in the Healthcare Industry
For further information please contact Adam Collins, PLG Administrator:
admin@plg-uk.com
00 44 (0)1737 356391
Please enter your email address* and the password provided by PLG to send a message.
* Please enter the email address used to register for this event.
Bayer HealthCare Gold Sponsor |
Evaluate Silver Sponsor |
Fine Foods Silver Sponsor |
goMed2Med Silver Sponsor |
PwC Silver Sponsor |
China Medical System Holdings Bronze Sponsor |
Hermes Pharma Bronze Sponsor |
09.00 - 10.00 | Registration |
10.00 - 10.15 | Welcome and Introduction THOMAS HOEGN, President, EPLC & IRINA STAATZ-GRANZER, President, Pharma Lizenz Club Deutschland (PLCD) |
SESSION A Deal Environment Review Across The Healthcare Sector Explaining How M&A is Affecting Their Business |
|
10.15 - 10.45 | Innovation: Where Are New Products Coming From? Are the Pharma Company Pipelines Empty? JONATHAN DE PASS, Chairman, Evaluate |
10.45 - 11.15 | Recent Trends in Medical Devices Business Development AMIR BABAEI-MAHANI, Senior Director External Innovation & Enabling Technologies, DePuy Synthes, Companies of Johnson & Johnson |
11.15 - 11.45 | M&A From the OTC Perspective THORSTEN UMLAND, VP and Head, Business Development & Licensing Consumer Care, Bayer HealthCare |
11.45 - 12.15 | Generics Viewpoint: The Impact of M&A Activity on Deals CLAUDIO ALBRECHT, Co-Founder and Managing Partner, Albrecht, Prock & Partners |
12.15 - 13.00 | Panel Discussion |
13.00 - 14.30 | Lunch |
14.30 - 17.00 | SESSION B TALKING TABLES Good Partnering Practices in the Healthcare Industry - a Swiss HLG Initiative: 1. Scouting & Prospecting 2. Evaluation and Due Diligence 3. Negotiation & Execution 4. Intergration & Alliance Management 5. Conflict Resolution and Termination and 6. Breaking Through the Invisible Cultural Boundaries Within Europe Each Table Will Be Run Twice |
17.00 - 19.00 | Networking Drinks Reception Hilton Berlin Ballroom Foyer Area |
09.00 - 09.30 | Feedback and Conclusions from Previous Days Talking Tables |
SESSION C Consolidation and Risk Sharing Between Big Pharma Companies |
|
09.30 - 10.15 | Practical BD Experience of Risk Sharing, Co-Development and Co-Commercialisation JOESPH HAVRILLA, Head of Alliance Management, Bayer HealthCare |
10.15 - 11.00 | Partnership Deals - Strengths and Risk Sharing JUERGEN BECK, Head of Business Development & Licensing / Strategic Transactions, Boehringer Ingelheim |
11.00 - 11.30 | Break |
SESSION D Impact of the Changing Deal Environment for Mid-Sized Companies |
|
11.30 - 12.15 | Market Access BIRGIT FRIEDMANN, Senior Director, Market Access, Quintiles |
12.15 - 13.00 | 2016 Transactional Trends: Key Issues for Cross Border Deals; Focus on Emerging and Mid-Sized Companies GREG BENNING, Managing Director, Head of Financial Advisory & MARK A. KING, Senior Partner, Back Bay Life Science Advisors |
13.00 - 14.00 | Lunch |
SESSION E Challenges Securing Deals in Other Countries |
|
14.00 - 14.45 | Opportunities & Difficulties in Emerging Markets for Non-Generic Products REINER CHRISTENSEN, CEO, Chameleon Pharma Consulting |
14.45 - 15.30 | Japan: Cultural Differences Impact on Deal Making |
15.30 - 16.00 | Break |
16.00 - 16.45 | Bringing Pharmaceutical Products to China: Opportunities and Challenges HUAIZHENG PENG, General Manager, International Operations, China Medical System Holdings |
16.45 - 17.30 | Business Development in India: More Than Just Generics RAVI SODHA, Senior Director, Business Development, Actelion Pharma |
18.00 - 22.00 | Drinks Reception and Gala Dinner at Adagio Dress Code: Business Suits |
SESSION F Business Models Proving Resistant to Pharma M&A |
|
09.00 - 09.45 | Deal Structure Evolution: Morphing Into a Biopharma Company by Doing Major Pharma Deals BARBARA KREBS-POHL, Head of Business Development, MorphoSys |
09.45 - 10.30 | How Bavarian Nordic Built a Multi-Million Business and Commercial Infrastructure Through Deal-Making JUERGEN LANGHAERIG, VP Business Development, Bavarian Nordic |
10.30 - 11.00 | Break |
11.00 - 11.45 | Orphan Drugs Strategy DANKWART RAUSCHER, Head of Portfolio & Licensing Management, Recordati Pharma |
11.45 - 12.30 | Deal Making in the New Financial Environment: Results of the PLG Healthcare Deals Finance Survey KLAUS MALECK, CEO, Tetec & ROGER DAVIES, Director, Redpharma |
12.30 - 14.00 | Lunch and CLOSE |
Hilton Berlin
Mohrenstrasse 30,
10117 Berlin,
Germany
You must be logged in to access the downloads.